Key lessons for cell & gene therapy and mRNA therapeutic development from COVID-19 mRNA vaccine approvals
Sponsor
The development of mRNA therapeutics is not a new phenomenon - for over a decade, numerous mRNA therapeutics have entered the clinical pipeline.
However, the key role played by mRNA-based vaccines in battling the COVID-19 pandemic has resulted a rapid acceleration in the development timeframe of this technology field, bringing two mRNA-based products from the clinical phase to FDA approval in short order.
This webinar will feature a Roundtable discussion between thought-leaders from both the mRNA vaccine and therapeutic spheres. This unique and timely cross-pollination of experiences and ideas will answer two central questions for novel biotherapeutic developers: what can the cell and gene therapy field learn from the prophylactic vaccine approvals, and how will the vaccines’ success help accelerate the progress of mRNA therapeutics through the clinical towards commercialization?
- Development challenges diverse mRNA therapeutic approaches/platforms face today
- Key differences and current bottlenecks in mRNA downstream processing - how to ensure product quality and safety
- Specific requirements and considerations for therapeutic mRNA applied in the cell therapy transfection setting
- Lessons the vaccine and therapeutic fields can learn from each other in terms of the development of solutions applicable to the various component technology areas
- Relevant learnings from the established biopharma world (e.g. mAbs) to accelerate development of mRNA therapeutics
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Empowering patient care: in-process and quality control solutions for cellular therapies
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
